Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2018 02:00 ET | Source: KDventures AB

Karolinska Development: Bokslutskommuniké för januari - december 2017

STOCKHOLM - den 15 februari 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin bokslutskommuniké för januari - december 2017 med ett positivt resultat både för fjärde...
February 15, 2018 02:00 ET | Source: KDventures AB

Karolinska Development: Q4 and 2017 Year-End Report - January-December

STOCKHOLM - 15 February 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Q4 and 2017 Year-End Report with a positive quarterly and full-year result. The full report is...
December 29, 2017 13:30 ET | Source: KDventures AB

Karolinska Developments styrelseordförande lämnar sitt uppdrag

STOCKHOLM den 29 december 2017. Karolinska Development meddelar idag att bolagets styrelseordförande Niclas Adler beslutat att av personliga skäl lämna sitt uppdrag. Professor Hans Wigzell,...
December 29, 2017 13:30 ET | Source: KDventures AB

Karolinska Development's Chairman of the Board resigns from his position

STOCKHOLM, December 29, 2017. Karolinska Development announces today that the company's Chairman of the Board, Niclas Adler, has decided to leave his assignment for personal reasons. Professor Hans...
December 21, 2017 09:22 ET | Source: KDventures AB

BioArctic, a company in Karolinska Development's portfolio, announces that the Phase 2b study of BAN2401 in early Alzheimer's Disease continues toward 18-month endpoint

STOCKHOLM, December 21, 2017. Karolinska Development announces today that BioArctic's drug candidate BAN2401 did not meet the criteria for success at a 12-month interim analysis of a Phase IIb study...
December 21, 2017 09:22 ET | Source: KDventures AB

BioArctic, a company in Karolinska Development's portfolio, announces that the Phase 2b study of BAN2401 in early Alzheimer's Disease continues toward 18-month endpoint

STOCKHOLM, December 21, 2017. Karolinska Development announces today that BioArctic's drug candidate BAN2401 did not meet the criteria for success at a 12-month interim analysis of a Phase IIb study...
December 20, 2017 04:00 ET | Source: KDventures AB

Karolinska Development's portfolio company Modus Therapeutics announces publication of Phase I/II data demonstrating anti-adhesive properties of sevuparin

STOCKHOLM, December 20, 2017. Karolinska Development announced today that data from a Phase I/II study of sevuparin in malaria patients was published in an on-line version of the renowned scientific...
December 20, 2017 04:00 ET | Source: KDventures AB

Karolinska Development's portfolio company Modus Therapeutics announces publication of Phase I/II data demonstrating anti-adhesive properties of sevuparin

STOCKHOLM, December 20, 2017. Karolinska Development announced today that data from a Phase I/II study of sevuparin in malaria patients was published in an on-line version of the renowned scientific...
December 14, 2017 02:00 ET | Source: KDventures AB

Karolinska Development's portfolio company Promimic receives FDA approval for HAnano Surface for use on dental implants

STOCKHOLM, December 14, 2017. Karolinska Development announces today that the portfolio company Promimic has received approval from the U.S. Food and Drug Administration (FDA) for the use of HAnano...
December 14, 2017 02:00 ET | Source: KDventures AB

Karolinska Development's portfolio company Promimic receives FDA approval for HAnano Surface for use on dental implants

STOCKHOLM, December 14, 2017. Karolinska Development announces today that the portfolio company Promimic has received approval from the U.S. Food and Drug Administration (FDA) for the use of HAnano...